Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...
Incyte received a Rare Pediatric Disease Priority Review Voucher tied to zilurgisertib’s FOP approval, while Mirum plans U.S.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient ...
Pharmaceutical Executive spoke with Michael Abrams, managing partner at global healthcare consultancy Numerof & Associates ...
PharmD, is Chief Compliance and Clinical Officer at Strive Pharmacy. With more than 10 years of pharmacy leadership experience and over four years at Strive, he oversees regulatory compliance, ...
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
With healthcare costs dominating the conversation in recent years, the topic of employer-covered healthcare is a key issue.
Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with ...
Novo Nordisk secured Pharmashell access for up to five peptide programs, targeting long-acting injectable profiles and offering Nanexa >$1.33B total consideration plus low single-digit royalties.
FDA cleared belzutifan 120 mg plus lenvatinib 20 mg daily for advanced RCC with a clear cell component after prior PD-1/PD-L1 inhibitor exposure. LITESPARK-011 randomized 747 patients to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results